ctDNA

16 · 20 / page

Ask MedXY AI

Latest news

Tag

Dermatologycancer surveillancectDNA

Circulating Tumor DNA Outperforms Merkel Cell Polyomavirus Antibodies for Monitoring Recurrence in Merkel Cell Carcinoma

By MedXY|Jul 14, 2026

A multicenter cohort study demonstrates that circulating tumor DNA (ctDNA) is more accurate than Merkel cell polyomavirus (MCPyV) antibody testing in detecting recurrence of Merkel cell carcinoma, improving patient surveillance and risk str

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

ctDNA

Latest news

Circulating Tumor DNA Outperforms Merkel Cell Polyomavirus Antibodies for Monitoring Recurrence in Merkel Cell Carcinoma

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

Early ctDNA MRD After Two Cycles Identifies Distinct Relapse Risk Groups in Advanced Hodgkin Lymphoma

Baseline Circulating Tumor DNA as a Prognostic Biomarker in Untreated Follicular Lymphoma: Insights from the GALLIUM Trial

Liquid Biopsy Predicts Recurrence in HPV-Independent Head and Neck Cancer Months Before Imaging

Preoperative ctDNA Detects Occult Nodal Metastasis and Predicts Recurrence in Early-Stage Esophageal Squamous Cell Carcinoma

Beyond the Scalpel: How ctDNA Blood Tests are Revolutionizing Head and Neck Cancer Monitoring

Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer

Low-Pass Whole Genome Bisulfite Sequencing for ctDNA Monitoring in Metastatic Colorectal Cancer: Insights from the VALENTINO Trial

Beyond Detection: How ctDNA Dynamics Predict Treatment Success in Advanced Breast Cancer

Postoperative ctDNA Identifies Stage III Colon Cancer Patients Who May Benefit from Adjuvant Celecoxib

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: DYNAMIC-III Validates Prognosis but Questions Intensification

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer: Translating Precision Oncology into Improved Outcomes

Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

Early ctDNA Variation as a Prognostic Biomarker in dMMR/MSI-H Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors: Insights from the SAMCO-PRODIGE 54 Trial